Collaborative Network for Clinical Research on Immune Tolerance
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 15, 2026
Can you apply?
This grant is for research institutions seeking to advance clinical understanding of immune tolerance mechanisms. Eligible applicants typically include research universities, medical schools, hospital systems, and nonprofit research organizations with the capacity to conduct clinical trials. The program supports collaborative, multi-site research networks investigating tolerance in transplantation, autoimmune diseases, and allergic conditions. Applicants must demonstrate institutional commitment, qualified research personnel, and patient populations for clinical trial enrollment.
Not the right fit? Find grants for your organization in 5 questions →
Key dates
- Jun 24, 2026 Applications open
- Jan 29, 2027 Application deadline in 197 days
- Feb 1, 2028 Award announced
- Feb 1, 2028 Project start
Program description
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission through the continued support of the Collaborative Network for Clinical Research on Immune Tolerance. The purpose of this program is to enhance understanding of the underlying mechanisms of the induction, maintenance, and loss of immune tolerance in humans; and to develop improved tolerogenic interventions for the prevention and treatment of immune system mediated diseases (including transplant rejection, autoimmune diseases, and asthma and allergic diseases). The three major scientific goals include: 1) conduct clinical trials to determine the safety and efficacy of promising tolerogenic strategies in liver, kidney and pancreatic islet transplantation; allergic diseases and asthma; and autoimmune diseases; 2) investigate the basic mechanisms of immune tolerance in these diseases as an integral part of clinical trials; and 3) develop, refine and validate immune assays to monitor the induction, maintenance, and loss of tolerance in these disorders. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Who can apply
Eligible applicants
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 Federal Grant Application
- Project Narrative
- Budget and Budget Narrative
- Biographical Sketches (Research Team)
- Letters of Support/Institutional Commitment
- Data Management/Sharing Plan
- Timeline and Milestones
Program contact
- 👤 Division of Allergy, Immunology and Transplantation
- 📧 ITN_UM1@mail.nih.gov
- 📞 Please contact via email.
Funding track record
Recent awards under CFDA 93.855 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$246,626,852
-
$201,437,825
-
$185,816,804
-
$180,737,624
-
$136,265,880
-
$116,817,868
-
$93,394,862
-
$89,845,851
-
$74,456,241
-
$72,987,380
Top States by Funding
- CA 8 awards $696.2M
- MA 6 awards $602.8M
- NY 6 awards $335.0M
- TX 3 awards $280.9M
- GA 5 awards $257.9M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.855). How funding has trended year over year.
| 2024 | $4,073,812,529 | |
| 2025 | $4,378,235,639 | |
| 2026 est. | $4,299,426,996 |
FAQ
What types of organizations can apply for this grant?
Research institutions including universities, medical centers, and nonprofit research organizations can apply. Your institution must have infrastructure to support clinical trials and regulatory compliance.
What research activities are funded?
Clinical trials testing tolerogenic strategies, mechanistic studies of immune tolerance, and development of immune assays. All activities must relate to transplantation, autoimmune diseases, or allergic conditions.
Is cost-sharing required?
No cost-sharing is required for this cooperative agreement.
When is the deadline?
The deadline is January 29, 2027. This is a fixed deadline, not rolling.
How competitive is this funding?
This is a highly competitive program. Strong preliminary data, experienced clinical teams, and feasible trial designs improve competitiveness significantly.
💡 Tips for applicants
- Emphasize your institution's clinical trial infrastructure and regulatory compliance capabilities. NIH values experienced research networks with proven enrollment capacity.
- Present preliminary data demonstrating the promise of your proposed tolerogenic intervention. Pilot data significantly strengthens competitiveness.
- Design realistic patient enrollment targets with institutional patient population data to support feasibility.
- Include letters of commitment from collaborating sites if this is a multi-institutional application.
- Clearly explain how your work advances understanding of tolerance mechanisms, not just clinical outcomes.
⚠️ Common mistakes
Submitting weak preliminary data or unproven tolerogenic approaches. Underestimating the resources needed for multi-year clinical trials or failing to address regulatory and safety monitoring plans. Unclear mechanistic hypotheses linking clinical observations to immune tolerance biology.
Similar grants
- OPEN Translational Transplantation Tolerance Cooperative Study Group — National Institutes of Health
- OPEN Asthma and Allergic Diseases Cooperative Research Centers — National Institutes of Health
- OPEN Childhood Asthma in Urban Settings Clinical Research Network — National Institutes of Health
- OPEN Clinical Data, Safety and Statistical Centers (CDSSC) — National Institutes of Health
- OPEN Clinical Trials in Organ Transplantation in Children and Adults — National Institutes of Health